Conclusions
neuroinflammation, brain injury
In this study, erythropoietin treatment did not attenuate biomarkers of neuroinflammation or brain injury in neonates with HIE. In the sample of 180 infants, biomarkers measured at baseline (C5a, IL-6, and NSE) and day 4 (IL-8, tau, and UCHL1) incrementally improved estimation of 2-year outcomes when added to clinical characteristics in this high-risk population.